Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041197 · ClinicalTrials.gov registry record · Phase 3
Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 732
- Enrollment target
NCT00041197: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00041197 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 732 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00041197, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 732 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying imatinib mesylate to see how well it works compared to placebo in treating patients with primary gastrointestinal stromal tumor that has been completely removed by surgery. Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for patients with primary gastrointestinal stromal tumor that has been completely removed by surgery.
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- DRUG imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 2002-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00041197
The ClinicalTrials.gov registry entry for NCT00041197 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 732 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00041197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00041197 about?
NCT00041197 is a clinical study titled "Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery". This randomized phase III trial is studying imatinib mesylate to see how well it works compared to placebo in treating patients with primary gastrointestinal stromal tumor that has been completely removed by surgery. Imatinib mesylate may interfere with the growth of tumor cells and may be an effect...
What is the current status of trial NCT00041197?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 732 participants. The study started on 2002-06.
What interventions are being tested in trial NCT00041197?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00041197?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.